Statement: less than 1% of either cohort of the primary trial was effect by either Pancytopenia or Coagulopathy.
Primary_evidence: Adverse Events 1:   Total: 128/425 (30.12%)   Febrile neutropenia *2/425 (0.47%)   Anaemia *2/425 (0.47%)   Pancytopenia *2/425 (0.47%)   Coagulopathy *1/425 (0.24%)   Idiopathic thrombocytopenic purpura *0/425 (0.00%)   Microangiopathic haemolytic anaemia *1/425 (0.24%)   Neutropenia *0/425 (0.00%)   Pericardial effusion *1/425 (0.24%)   Acute coronary syndrome *1/425 (0.24%) Adverse Events 2:   Total: 129/406 (31.77%)   Febrile neutropenia *6/406 (1.48%)   Anaemia *0/406 (0.00%)   Pancytopenia *0/406 (0.00%)   Coagulopathy *0/406 (0.00%)   Idiopathic thrombocytopenic purpura *1/406 (0.25%)   Microangiopathic haemolytic anaemia *0/406 (0.00%)   Neutropenia *1/406 (0.25%)   Pericardial effusion *1/406 (0.25%)   Acute coronary syndrome *0/406 (0.00%)